5.85Open5.85Pre Close0 Volume14 Open Interest2.50Strike Price0.00Turnover0.00%IV-0.71%PremiumOct 18, 2024Expiry Date5.91Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.43Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Wave Life Sciences Stock Discussion
In a notable transaction, GSK (LON:GSK) plc, a major player in the pharmaceutical industry, has recently increased its stake in Wave Life Sciences Ltd . (NASDAQ:WVE). The acquisition involved the purchase of 2,791,930 ordinary shares at a price of $8.00 per share, amounting to a total investment of $22.3 million.
This strategic move by GSK plc, which is known for its diverse portfolio of healthca...
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Wave Life Sciences announced positive interim data from the FORWARD-53 clinical trial evaluating WVE-N531 in boys with Duchenne Muscular Dystrophy (DMD) amenable to exon 53 skipping. Key findings include:
- Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of ...
Wave Life Sciences Announces FDA Has Granted Rare Pediatric Disease Designation To WVE-N531 For Treatment Of Duchenne Muscular Dystrophy
No comment yet